Ido1 activation occurs commonly in tumor cells and/or tumor-draining lymph nodes (TDLNs), and pharmacological inhibition of IDO1 with 1-MT has been shown to result in T-cell-dependent antitumor responses in animal models [8, 22–27]. The gene discussed is IDO1; the disease is neoplasm.